Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
French cancer focused biotech Transgene has appointed two seasoned leaders in oncology who will be instrumental in advancing the company’s innovative immunotherapy programs 10 September 2024
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024
Swiss biotech ImmunOs Therapeutics today announced the appointment of Dr Constanze Guenther as senior vice president, CMC and technical development. 19 September 2023
Among last week’s notable news, US drug developer Crinetics Pharmaceuticals released surprisingly good Phase III clinical trial results for its paltusotine in acromegaly. Germany’s Immatics has entered into a collaboration with the USA’s Moderna to develop mRNA-based cancer therapies. US cell and gene based immune-oncology drug developer 2seventry bio last week announced it is cutting its work force by 40% as part of a cost-cutting restructuring, and that chief executive Nick Leschly is stepping down. Also of note, Alnylam received a positive US Food and Drug Administration (FDA) advisory committee vote for its ATTR-cardiomyopathy candidate Onpattro (patisiran). 17 September 2023
US cell and gene therapy biotech 2seventy bio had a bumpy ride this morning, after it announced a restructuring of its business operations and research and development model to significantly reduce costs while supporting the execution of a prioritized plan for the long-term growth of the company. 12 September 2023
Jane Grogan has been named as executive vice president, head of research at US biotech major Biogen, with the appointment taking effective on October 2. 6 September 2023
Shares of Swedish enzyme technology firm Hansa Biopharma were up 3% at 43.82 kronor, after it announced the appointment of Dr Hitto Kaufmann as its chief scientific officer (CSO) effective December 1, 2023. 1 September 2023
Privately-held Dutch immune-mediated inflammatory diseases company Citryll is the latest stop for experienced biotech chief executive Eduardo Bravo. 29 August 2023
Belgian G-protein coupled receptor (GPCR) company Confo Therapeutics today announced the appointment of Dieter Weinand as independent chairman of its board of directors, succeeding John Berriman, who is retiring from his current position. 29 August 2023
German developer of next-generation CAR-T cell therapies for cancer patients, T-CURX GmbH, has announced the appointments of Dr Hans-Peter (HP) Gerber as chairman. 28 August 2023
Swedish contract development and manufacturing organization (CDMO) NorthX Biologics has appointed Janet Hoogstraate as its new chief executive. 24 August 2023
Seattle, USA-based Alpine Immune Sciences, an immunotherapy company developing innovative treatments for autoimmune and inflammatory diseases, has named Christina Yi its new chief technology officer. 24 August 2023
Flagship Pioneering company Alltrna, which is unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, has appointed Chris Henderson, as chief scientific officer and promoted William (Will) Kiesman, to the post of chief technology officer. 19 August 2023
Privately-held Resolution Therapeutics, a UK biopharmaceutical company developing macrophage cell therapies to treat advanced liver disease, has named Amir Hefni as chief executive. 14 August 2023
US adeno-associated virus (AAV) specialist Voyager Therapeutics has announced the appointment of Beth Shafer as chief business officer (CBO). 11 August 2023
US cancer-focused biotech Foghorn Therapeutics today announced that Dr Alfonso Quintás-Cardama will join the company as chief medical officer, on September 11, 2023. 8 August 2023
San Diego, USA-based cancer focussed biotech Viracta Therapeutics today announced the appointment of Dr Darrel Cohen, as chief medical officer (CMO), with immediate effect. 7 August 2023